Free Access
Med Sci (Paris)
Volume 27, Number 12, Décembre 2011
Page(s) 1097 - 1105
Section M/S Revues
Published online 23 December 2011
  1. Sadler JE. Von Willebrand factor, ADAMTS13 and thrombotic thrombocytopenic purpura. Blood 2008 ; 112 : 11–18. [CrossRef] [PubMed] [Google Scholar]
  2. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloprotease family. Blood 2001 ; 98 : 1662–1666. [CrossRef] [PubMed] [Google Scholar]
  3. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001 ; 276 : 41059–41063. [CrossRef] [PubMed] [Google Scholar]
  4. Soejima K, Mimura N, Hirashima M, et al. A novel metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem 2001 ; 130 : 475–480. [CrossRef] [PubMed] [Google Scholar]
  5. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 ; 413 : 488–494. [CrossRef] [PubMed] [Google Scholar]
  6. Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005 ; 85 : 780–788. [CrossRef] [PubMed] [Google Scholar]
  7. Turner N, Nolasco L, Tao Z, et al. Human endothelial cells synthesize and release ADAMTS13. J Thromb Haemost 2006 ; 4 : 1396–1404. [CrossRef] [PubMed] [Google Scholar]
  8. Liu L, Choi H, Bernardo A, et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005 ; 3 : 2536–2544. [CrossRef] [PubMed] [Google Scholar]
  9. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996 ; 87 : 4223–4234. [PubMed] [Google Scholar]
  10. Tsaï HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996 ; 87 : 4235–4244. [PubMed] [Google Scholar]
  11. Furlan M, Robles R, Morselli B, et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999 ; 81 : 8–13. [PubMed] [Google Scholar]
  12. Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand’s disease. Blood 1998 ; 91 : 2032–2044. [PubMed] [Google Scholar]
  13. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005 ; 280 : 71773–71778. [CrossRef] [PubMed] [Google Scholar]
  14. Padilla A, Moake JL, Bernardo A, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelia cell surface. Blood 2004 ; 103 : 2150–2156. [CrossRef] [PubMed] [Google Scholar]
  15. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibα to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 2004 ; 101 : 10578–10583. [CrossRef] [Google Scholar]
  16. Majerus EM, Zheng XL, Tuley EA, Sadler JE. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 2003 ; 278 : 46643–46648. [CrossRef] [PubMed] [Google Scholar]
  17. Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003 ; 102 : 3232–3237. [CrossRef] [PubMed] [Google Scholar]
  18. Zhang P, Pan W, Rux AH, et al. The cooperative activity between the carboxy-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007 ; 110 : 1887–1894. [CrossRef] [PubMed] [Google Scholar]
  19. Davis AK, Makar RS, Stowell CP, et al. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion 2009 ; 49 : 206–213. [CrossRef] [PubMed] [Google Scholar]
  20. Zanardelli S, Chion AC, Groot E, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood 2009 ; 114 : 2819–2828. [CrossRef] [PubMed] [Google Scholar]
  21. Tao Z, Wang Y, Choi H, et al. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood 2005 ; 106 : 141–143. [CrossRef] [PubMed] [Google Scholar]
  22. Gao W, Anderson PJ, Majerus EM, et al. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombic ADAMTS13 metalloprotease. Proc Natl Acad Sci USA 2006 ; 103 : 19099–19104. [Google Scholar]
  23. Veyradier A, Girma JP. Assays of von ADAMTS13 activity. Semin Hematol 2004 ; 41 : 41–47. [CrossRef] [PubMed] [Google Scholar]
  24. Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005 ; 129 : 93–100. [CrossRef] [PubMed] [Google Scholar]
  25. Tripodi A, Chantarangkul V, Böhm M, et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004 ; 2 : 1601–1609. [CrossRef] [PubMed] [Google Scholar]
  26. Kremer-Hovinga J, Mottini M, Lämmle B. Measurement of ADAMTS13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006 ; 4 : 1146–1148. [CrossRef] [PubMed] [Google Scholar]
  27. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001 ; 98 : 2730–2735. [CrossRef] [PubMed] [Google Scholar]
  28. Schmugge M, Dunn MS, Amankwah KS, et al. The activity of the von Willebrand factor-cleaving protease ADAMTS-13 in newborn infants. J Thromb Haemost 2003 ; 2 : 228–233. [CrossRef] [Google Scholar]
  29. Sanchez-Luceros A, Farias CE, Amaral MM, et al. Von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004 ; 92 : 1320–1396. [PubMed] [Google Scholar]
  30. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008 ; 3 : 249–277. [CrossRef] [PubMed] [Google Scholar]
  31. Moschcovitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924 ; 24 : 21–24. [Google Scholar]
  32. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982 ; 307 : 1432–1435. [CrossRef] [PubMed] [Google Scholar]
  33. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 antibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005 ; 106 : 1262–1267. [CrossRef] [PubMed] [Google Scholar]
  34. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS13 antibodies feature (Ig isotype titer and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with an undetectable ADAMTS13 activity. Blood 2007 ; 109 : 2815–2822. [PubMed] [Google Scholar]
  35. Scully M. Inhibitory anti-ADAMTS13 antibodies: measurement and clinical application. Blood Rev 2010 ; 24 : 11–16. [CrossRef] [PubMed] [Google Scholar]
  36. Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010 ; 116 : 2005–2010. [CrossRef] [PubMed] [Google Scholar]
  37. Coppo P, Busson M, Veyradier A, et al. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. J Thromb Haemost 2010 ; 8 : 856–859. [CrossRef] [PubMed] [Google Scholar]
  38. Camilleri RS, Cohen H, Mackie IJ, et al. Prevalence of the ADAMTS 13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost 2008 ; 6 : 331–338. [PubMed] [Google Scholar]
  39. Coppo P, Benghoufa D, Veyradier A, et al. Prevalence and clinical significance of anti-nuclear antibodies in adult thrombotic microangiopathies. Medicine (Balt) 2004 ; 83 : 233–244. [CrossRef] [Google Scholar]
  40. Lotta LA, Garagiola I, Palla R, et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010 ; 31 : 11–19. [CrossRef] [PubMed] [Google Scholar]
  41. Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006 ; 107 : 118–125. [CrossRef] [PubMed] [Google Scholar]
  42. Westrick RJ, Ginsburg D.. Modifier genes for disorders of thrombosis and hemostasis. J Thromb Haemost 2009 ; 7 : (suppl 1) : 132–135. [CrossRef] [Google Scholar]
  43. Chauhan AK, Walsh MT, Zhu G, et al. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008 ; 111 : 3452–3457. [CrossRef] [PubMed] [Google Scholar]
  44. Plaimauer B, Kremer Hovinga J, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011 ; 9 : 936–944. [CrossRef] [PubMed] [Google Scholar]
  45. Laje P, Shang D, Cao W, et al. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood 2009 ; 113 : 2172–2180. [CrossRef] [PubMed] [Google Scholar]
  46. Niiya M, Endo M, Shang D, et al. Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol Ther 2009 ; 17 : 34–41. [CrossRef] [PubMed] [Google Scholar]
  47. Trionfini P, Tomasoni S, Galbusera M, et al. Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. Gene Ther 2009 ; 16 : 1373–1379. [CrossRef] [PubMed] [Google Scholar]
  48. Girma JP, Veyradier A, Meyer D. ADAMTS 13, la protéase spécifique du facteur Willebrand. Med Sci (Paris) 2002 ; 18 : 15–17. [CrossRef] [EDP Sciences] [Google Scholar]
  49. Chauhan AK, Kisucka J, Brill A, et al. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008 ; 205 : 2065–2074. [CrossRef] [PubMed] [Google Scholar]
  50. Fujioka M, Hayakawa K, MishimaK, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 2010 ; 115 : 1650–1653. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.